HD2A RASC-SUD Implementation Support Core

HD2A RASC-SUD 实施支持核心

基本信息

  • 批准号:
    10708983
  • 负责人:
  • 金额:
    $ 53.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-30 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative bolsters research across NIH to improve treatment for opioid misuse and addiction and to develop concrete strategies capable of providing rapid and durable solutions to the opioid crisis. SUD IMPLEMENTATION SUPPORT CORE: PROJECT SUMMARY/ABSTRACT Drug overdose fatalities have continued to rise despite massive federal investment in developing and disseminating evidence-based pharmacological and behavioral interventions for substance use disorders (SUDs). Attempts to move the needle on overdose deaths have stalled because of challenges translating research knowledge and evidence-based SUD interventions into public health practice. Access to evidence- based SUD interventions remains woefully limited throughout the U.S. health care system, particularly for historically marginalized populations such as Black/African-Americans, Native Hawaiians/Pacific Islanders, Asian Americans, and the uninsured. Equitable translation of research findings into practice is the domain of dissemination and implementation (D&I) science. A core component of the HD2A Research Adoption Support Center (RASC), the SUD Implementation Support (SUD-IS) Core will bring the best of D&I science to the Innovation Projects to guide the selection, implementation, and sustainment of evidence-based, locally appropriate SUD interventions to reduce overdose risk in hard hit communities. Core leadership will unify implementation scientists and SUD researchers - with the proximal goal of enhancing the impact of the Innovation Projects and the ultimate goal of improving public health - by leveraging cutting-edge D&I measures and methods, and capitalizing on our team’s commitment to team science. Thematically and operationally in tandem with the RASC and other cores, the SUD-IS Core will elevate the Innovation Projects through dynamic and iterative phases of ASSESS, ASSIST, and ADVANCE. We will first ASSESS the current state of evidence for SUD interventions in order to: a) develop a systematic catalog of evidence-based and emerging practices; and b) develop an SUD Intervention D&I Resource Guide for the Innovation Projects and any SUD intervention implementation project based on five key D&I constructs (e.g., contextual determinants, evidentiary support for the intervention, stakeholder engagement, implementation strategies, and implementation outcomes including equity and stigma). We will then ASSIST the Innovation Projects using information gathered in the ASSESS phase in order to: a) enhance motivation to enhance their studies with tailored D&I approaches that draw upon Core expertise; b) provide a D&I Implementation Support Plan and use a shared decision-making approach to determine how best to offer technical assistance; and c) co-lead the RASC Learning Collaborative. Finally, we will ADVANCE the Innovation Projects’ activities with respect to sustainment, equity, and stigma reduction: linking projects with the field at large, promoting impacts on policy/financing and facilitating ongoing stakeholder engagement towards advocacy. Perfectly aligned with the RASC, together we take a major step toward closing the persistent and inequitable gap of access to proven pharmacologic and psychosocial treatments for SUD.
这项研究是NIH帮助结束成瘾长期(Hear)倡议的一部分,该倡议旨在加快科学解决国家阿片类药物公共健康危机的速度。NIH Hear Initiative支持整个NIH的研究,以改善阿片类药物滥用和成瘾的治疗,并制定能够为阿片类药物危机提供快速和持久解决方案的具体战略。SUD实施支持核心:项目摘要/摘要尽管联邦政府在开发和传播针对物质使用障碍(SUDS)的循证药理学和行为干预措施方面进行了大量投资,但药物过量死亡人数仍在继续上升。由于将研究知识和以证据为基础的SUD干预措施转化为公共卫生实践的挑战,对过量用药死亡的指导努力已经停滞不前。可悲的是,在整个美国医疗保健系统中,获得循证SUD干预措施的机会仍然非常有限,特别是对于黑人/非裔美国人、夏威夷原住民/太平洋岛民、亚裔美国人和未参保的历史边缘人群。公平地将研究成果转化为实践是传播和实施(D&I)科学的领域。作为HD2A研究采用支持中心(RASC)的核心组成部分,SUD实施支持(SUD-IS)核心将为创新项目带来最好的研发科学,以指导选择、实施和维持以证据为基础的、当地适当的SUD干预措施,以降低重灾区的过量用药风险。核心领导层将通过利用尖端的D&I措施和方法,并利用我们团队对团队科学的承诺,将实施科学家和SUD研究人员统一起来-近期目标是增强创新项目的影响,最终目标是改善公共健康。在主题和操作上,与RASC和其他核心一起,SUD-IS核心将通过评估、协助和推进的动态和迭代阶段来提升创新项目。我们将首先评估SUD干预措施的证据现状,以便:a)制定基于证据的和新出现的做法的系统目录;以及b)根据五个关键的D&I结构(例如,背景决定因素、干预的证据支持、利益相关者参与、实施战略和实施结果,包括公平和耻辱),为创新项目和任何SUD干预实施项目制定一份SUD干预D&I资源指南。然后,我们将利用评估阶段收集的信息协助创新项目,以便:a)增强动力,利用利用核心专业知识的量身定制的D&I方法来加强其研究;b)提供D&I实施支持计划,并使用共享的决策方法来确定如何最好地提供技术援助;以及c)共同领导RASC学习协作。最后,我们将推进创新项目在可持续、公平和减少污名方面的活动:将项目与整个领域联系起来,促进对政策/融资的影响,并促进利益攸关方持续参与宣传。与RASC完全一致,我们共同朝着弥合长期和不公平的差距迈出了重要的一步,获得经过验证的SUD药物和心理社会治疗的机会。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sara J. Becker其他文献

Evaluation of sex disparities in opioid use among ED patients with sickle cell disease, 2006-2015.
2006-2015 年镰状细胞病 ED 患者阿片类药物使用性别差异的评估。
Randomized Clinical Trials in Behavioral Medicine
行为医学随机临床试验
Interventions for Substance Use Disorders in Adolescents: A Systematic Review
青少年药物使用障碍的干预措施:系统评价
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    D. Steele;Sara J. Becker;Kristin J. Danko;E. Balk;I. Saldanha;G. Adam;S. Bagley;C. Friedman;A. Spirito;Kelli Scott;E. Ntzani;Imani Saeed;Bryant T. Smith;J. Popp;T. Trikalinos
  • 通讯作者:
    T. Trikalinos
Proceedings of the 13th annual conference of INEBRIA
  • DOI:
    10.1186/s13722-016-0062-9
  • 发表时间:
    2016-09-01
  • 期刊:
  • 影响因子:
    3.200
  • 作者:
    Rod Watson;James Morris;John Isitt;Pablo Barrio;Lluisa Ortega;Antoni Gual;Kenneth Conner;Tracy Stecker;Stephen Maisto;Sophie Paroz;Caroline Graap;Véronique S Grazioli;Jean-Bernard Daeppen;Susan E Collins;Nicolas Bertholet;Jennifer McNeely;Vlad Kushnir;John A. Cunningham;Iain K Crombie;Kathryn B Cunningham;Linda Irvine;Brian Williams;Falko F Sniehotta;John Norrie;Ambrose Melson;Claire Jones;Andrew Briggs;Peter Rice;Marcus Achison;Andrew McKenzie;Elena Dimova;Peter W Slane;Véronique S. Grazioli;Susan E. Collins;Sophie Paroz;Caroline Graap;Jean-Bernard Daeppen;Stéphanie Baggio;Marc Dupuis;Joseph Studer;Gerhard Gmel;Molly Magill;Véronique S. Grazioli;Robert J. Tait;Lucinda Teoh;Erin Kelty;Elizabeth Geelhoed;David Mountain;Gary K. Hulse;Elina Renko;Shannon G. Mitchell;David Lounsbury;Zhi Li;Robert P. Schwartz;Jan Gryczynski;Arethusa S. Kirk;Marla Oros;Colleen Hosler;Kristi Dusek;Barry S. Brown;Deborah S. Finnell;Aisha Holloway;Li-Tzy Wu;Geetha Subramaniam;Gaurav Sharma;Sara Wallhed Finn;Sven Andreasson;Robert D. Dvorak;Matthew P. Kramer;Brittany L. Stevenson;Emily M. Sargent;Tess M. Kilwein;Sion K. Harris;Lon Sherritt;Sarah Copelas;John R. Knight;Noreen D Mdege;Jim McCambridge;Gallus Bischof;Anja Bischof;Jennis Freyer-Adam;Hans-Juergen Rumpf;Niamh Fitzgerald;Lisa Schölin;Paul Toner;Jan R. Böhnke;Laura J. Veach;Olivia Currin;Leigh Z. Dongre;Preston R. Miller;Elizabeth White;Emily C. Williams;Gwen T. Lapham;Jennifer J. Bobb;Anna D. Rubinsky;Sheryl L. Catz;Susan Shortreed;Kara M. Bensley;Katharine A. Bradley;Joanna Milward;Paolo Deluca;Zarnie Khadjesari;Rod Watson;Stephanie Fincham-Campbell;Colin Drummond;Kathryn Angus;Linda Bauld;Sophie Baumann;Katja Haberecht;Inga Schnuerer;Christian Meyer;Hans-Jürgen Rumpf;Ulrich John;Beate Gaertner;Marion Barrault-Couchouron;Marion Béracochéa;Vincent Allafort;Valérie Barthélémy;Hervé Bonnefoi;Emmanuel Bussières;Véronique Garguil;Marc Auriacombe;Marianne Saint-Jacques;Michel Dorval;Katia M’Bailara;Lidia Segura-Garcia;Nuria Ibañez-Martinez;Juan Manuel Mendive-Arbeloa;Manel Anoro-Perminger;Pako Diaz-Gallego;Mª Angeles Piñar-Mateos;Joan Colom-Farran;Marianthi Deligianni;Bertrand Yersin;Angeline Adam;Constance Weisner;Felicia Chi;Wendy Lu;Stacy Sterling;Kevin L. Kraemer;Kathleen A. McGinnis;David A. Fiellin;Melissa Skanderson;Adam J. Gordon;Jonathan Robbins;Susan Zickmund;P. Todd Korthuis;E. Jennifer Edelman;Nathan B. Hansen;Christopher J. Cutter;James Dziura;Lynn E. Fiellin;Patrick G. O’Connor;Stephen A. Maisto;Roger Bedimo;Cynthia Gilbert;Vincent C. Marconi;David Rimland;Maria Rodriguez-Barradas;Michael Simberkoff;Amy C. Justice;Kendall J. Bryant;Anne H Berman;Gillian W Shorter;Jeremy W Bray;Carolina Barbosa;Magnus Johansson;Reid Hester;William Campbell;Maria Lucia O. Souza Formigoni;André Luzi Monezi Andrade;Laisa Marcorela Andreoli Sartes;Christopher Sundström;Niels Eék;Martin Kraepelien;Viktor Kaldo;Claudia Fahlke;Lynn Hernandez;Sara J. Becker;Richard N. Jones;Hannah R. Graves;Anthony Spirito;Silke Diestelkamp;Lutz Wartberg;Nicolas Arnaud;Rainer Thomasius;Jacques Gaume;Véronique Grazioli;Cristiana Fortini;Zelra Malan;Bob Mash;Katherine Everett-Murphy;Véronique S. Grazioli;Joseph Studer;M. Mohler-Kuo;Nicolas Bertholet;Gerhard Gmel;Lawrence Doi;Helen Cheyne;Ruth Jepson;Vanesa Luna;Leticia Echeverria;Silvia Morales;Teresa Barroso;Ângela Abreu;Cosma Aguiar;Duncan Stewart;Angela Abreu;Riany M. Brites;Rafael Jomar;Gerson Marinho;Pedro Parreira;J. Paul Seale;J. Aaron Johnson;Dena Henry;Sharon Chalmers;Freida Payne;Linda Tuck;Akula Morris;Cátia Gonçalves;Bettina Besser;Cristina Casajuana;Hugo López-Pelayo;María Mercedes Balcells;Lídia Teixidó;Laia Miquel;Joan Colom;Kimberly A. Hepner;Katherine. J. Hoggatt;Andy Bogart;Susan. M. Paddock;Sarah L Hardoon;Irene Petersen;Fiona L Hamilton;Irwin Nazareth;Ian R. White;Louise Marston;Paul Wallace;Christine Godfrey;Elizabeth Murray;Hana Sovinová;Ladislav Csémy
  • 通讯作者:
    Ladislav Csémy
“Sounds like CSI:” How consumers of adolescent substance use disorder treatment perceive the term “evidence-based practice”
“听起来像犯罪现场调查:”青少年物质使用障碍的消费者如何看待“循证实践”一词的治疗

Sara J. Becker的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sara J. Becker', 18)}}的其他基金

HD2A RASC-SUD Implementation Support Core
HD2A RASC-SUD 实施支持核心
  • 批准号:
    10596437
  • 财政年份:
    2022
  • 资助金额:
    $ 53.86万
  • 项目类别:
C-DIAS RP 2: Implementing contingency management for stimulant use in specialty addiction treatment organizations
C-DIAS RP 2:在专业成瘾治疗组织中实施兴奋剂使用应急管理
  • 批准号:
    10668488
  • 财政年份:
    2022
  • 资助金额:
    $ 53.86万
  • 项目类别:
Implementing contingency management in opioid treatment centers across New England: A hybrid type 3 trial
在新英格兰各地的阿片类药物治疗中心实施应急管理:一项混合 3 型试验
  • 批准号:
    10665470
  • 财政年份:
    2022
  • 资助金额:
    $ 53.86万
  • 项目类别:
C-DIAS RP 2: Implementing contingency management for stimulant use in specialty addiction treatment organizations
C-DIAS RP 2:在专业成瘾治疗组织中实施兴奋剂使用应急管理
  • 批准号:
    10493960
  • 财政年份:
    2022
  • 资助金额:
    $ 53.86万
  • 项目类别:
Improving Outcomes of Adolescents in Residential Substance use Treatment via a Technology-Assisted Parenting Intervention
通过技术辅助育儿干预改善青少年住宅药物滥用治疗的结果
  • 批准号:
    10666175
  • 财政年份:
    2021
  • 资助金额:
    $ 53.86万
  • 项目类别:
Neighborhood perceptions and response to a technology-assisted parenting intervention for youth substance use
社区对针对青少年药物滥用的技术辅助育儿干预的看法和反应
  • 批准号:
    10836689
  • 财政年份:
    2021
  • 资助金额:
    $ 53.86万
  • 项目类别:
Implementing contingency management in opioid treatment centers across New England: A hybrid type 3 trial
在新英格兰各地的阿片类药物治疗中心实施应急管理:一项混合 3 型试验
  • 批准号:
    10400426
  • 财政年份:
    2018
  • 资助金额:
    $ 53.86万
  • 项目类别:
Implementing contingency management in opioid treatment centers across New England: A hybrid type 3 trial
在新英格兰各地的阿片类药物治疗中心实施应急管理:一项混合 3 型试验
  • 批准号:
    10215461
  • 财政年份:
    2018
  • 资助金额:
    $ 53.86万
  • 项目类别:
Adolescents with Substance Use Disorders Transitioning from Residential Treatment to the Community: Improving Outcomes via a Computer Assisted Parenting Program
患有药物滥用障碍的青少年从住院治疗过渡到社区:通过计算机辅助育儿计划改善治疗结果
  • 批准号:
    9034960
  • 财政年份:
    2016
  • 资助金额:
    $ 53.86万
  • 项目类别:
Adolescents with Substance Use Disorders Transitioning from Residential Treatment to the Community: Improving Outcomes via a Computer Assisted Parenting Program
患有药物滥用障碍的青少年从住院治疗过渡到社区:通过计算机辅助育儿计划改善治疗结果
  • 批准号:
    9263967
  • 财政年份:
    2016
  • 资助金额:
    $ 53.86万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 53.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 53.86万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 53.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 53.86万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 53.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 53.86万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 53.86万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 53.86万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 53.86万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 53.86万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了